PROJENX
ProJenX is a biopharmaceutical company that develops novel small molecule therapeutics that target motor neuron degenerative pathways. The company was founded in 2021 and is headquartered in Nissequogue, New York.
PROJENX
Industry:
Biopharma Biotechnology Health Care Therapeutics
Founded:
2021-01-01
Address:
New Suffolk, New York, United States
Country:
United States
Website Url:
http://www.projenx.com
Total Employee:
1+
Status:
Active
Contact:
917-268-1458
Total Funding:
21.1 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Google Font API Google Tag Manager WordPress Google Analytics Font Awesome Global Site Tag Sitelinks Search Box Google Analytics 4
Similar Organizations
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Harmony Biosciences
Harmony Biosciences is a pharmaceutical company that develops and commercializes novel therapies for rare neurological disorders.
Silverback Therapeutics
Silverback Therapeutics is a biopharmaceutical company that develops ImmunoTAC therapies targeting previously inaccessible disease pathways.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Current Employees Featured
Erin Fleming Co-Founder & VP Operations @ ProJenX
Co-Founder & VP Operations
2022-04-01
Eric Heil Interim CEO, Board Member & Chairman @ ProJenX
Interim CEO, Board Member & Chairman
2021-12-01
Stan Abel President & Chief Executive Officer @ ProJenX
President & Chief Executive Officer
2022-05-01
Founder
Investors List
The ALS Association
The ALS Association investment in Grant - ProJenX
Medical Excellence Capital
Medical Excellence Capital investment in Series A - ProJenX
Medical Excellence Capital
Medical Excellence Capital investment in Seed Round - ProJenX
Key Employee Changes
| Date | New article |
|---|---|
| 2022-05-18 | ProJenX Names Life Sciences Industry Veteran Stan E. Abel as CEO |
Official Site Inspections
http://www.projenx.com Semrush global rank: 15.71 M Semrush visits lastest month: 1
- Host name: 198.0.153.160.host.secureserver.net
- IP address: 160.153.0.198
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "ProJenX"
About - ProjenX WordPress Site
ProJenX was created out of a long-term research collaboration between Project ALS and researchers at Columbia University to rapidly develop and commercialize its lead therapy …See details»
ProJenX | MAP4K ALS and Neurodegenerative Disease …
Oct 19, 2024 ProJenX is the result of Project ALS’ research and dedication over the past 25 years, and takes with it the mission to find a new approach to effectively treating ALS. Project ALS recruits the world’s best scientists and …See details»
ProJenX - Crunchbase Company Profile & Funding
ProJenX may be growing as it has recently secured $15 million in funding to advance the development of its therapeutic product, prosetin, which is aimed …See details»
ProJenX | A Clinical-Stage ALS Biotechnology Company
Erin Fleming is a co-founder and Vice President of Research & Development at ProJenX. Prior to ProJenX launching in November 2021, Ms. Fleming was Director of Research Operations at …See details»
ProJenX - LinkedIn
ProJenX was created out of a long-term research collaboration between Project ALS and Columbia University to rapidly develop and commercialize its lead therapy candidate, prosetin, for people with ...See details»
ProJenX 2025 Company Profile: Valuation, Funding
ProJenX General Information Description. Operator of a clinical-stage biopharmaceutical company intended to treat neurodegenerative diseases. The company develops oral, brain-penetrant, small molecules shown in multiple …See details»
ProJenX - The Org
ProJenX is a biopharmaceutical company that develops novel small molecule therapeutics that target motor neuron degenerative pathways. The company was founded in 2021 and is …See details»
Projenx Company Profile - Office Locations, Competitors ... - Craft
Projenx has 5 employees at their 1 location and $20.1 m in total funding,. See insights on Projenx including office locations, competitors, revenue, financials, executives, subsidiaries and more …See details»
ProJenX - Contacts, Employees, Board Members, Advisors & Alumni
ProJenX is a biopharmaceutical company that develops novel small molecule therapeutics that target motor neuron degenerative pathways. ... Pricing. Log In. Log In. Experience the new …See details»
ProJenX - LifeScienceHistory.com
ProJenX projenx.com. 10 Bank St, Suite 560. 335 Old Mill Farm Road. White Plains, NY 10606. Company Info Year Established 2021. Contacts Stan Abel President & CEO Erin Fleming VP, …See details»
ProJenX - Funding, Financials, Valuation & Investors - Crunchbase
ProJenX is a biopharmaceutical company that develops novel small molecule therapeutics that target motor neuron degenerative pathways. New. Resources. ... How much funding has this …See details»
ProJenX Information - RocketReach
ProJenX is a clinical-stage biotechnology company with novel, targeted, brain-penetrant therapies to address neurodegenerative diseases, with an initial focus on ALS. ProJenX was created out …See details»
Leadership - ProjenX WordPress Site
Erin Fleming is a co-founder and Vice President of Research & Development at ProJenX. Prior to ProJenX launching in November 2021, Ms. Fleming was Director of Research Operations at …See details»
ProJenX launches to advance novel, targeted therapies for ALS …
Feb 16, 2022 A $5.1M seed financing was led by Medical Excellence Capital, which created ProJenX in collaboration with Project ALS, a leading nonprofit organization committed to ALS …See details»
ProJenX | Changing the Trajectory of ALS with Prosetin
ProJenX is a clinical-stage biotechnology company developing novel, targeted brain penetrant therapies to address neurodegenerative diseases, with an initial focus on ALS. At the heart of …See details»
ProJenX | Startup Profile and Investments - Bounce Watch
ProJenX is a clinical-stage biotech startup with a focus on developing novel, brain-penetrant therapies for neurodegenerative diseases, particularly ALS. Founded in 2021 in the United …See details»
ProJenX Names Life Sciences Industry Veteran Stan E. Abel as CEO
May 18, 2022 ProJenX and Unlearn Announce Partnership to Augment ALS Clinical Trial PRO-101 with Digital Twin Model . ProJenX, Inc., a clinical-stage biotechnology company …See details»
ProJenX Launches to Advance Novel, Targeted Therapies for ALS …
Feb 16, 2022 ProJenX is a clinical stage biotechnology company with novel, brain-penetrant, targeted therapies to address untreatable brain diseases, with an initial focus on ALS. …See details»
ProJenX - Updates, News, Events, Signals & Triggers - Crunchbase
ProJenX is a biopharmaceutical company that develops novel small molecule therapeutics that target motor neuron degenerative pathways. Search Crunchbase. Start Free Trial . Chrome …See details»
ProJenX - Tech Stack, Apps, Patents & Trademarks - Crunchbase
Jan 13, 2025 ProJenX is a biopharmaceutical company that develops novel small molecule therapeutics that target motor neuron degenerative pathways. New. Resources. Advanced …See details»